UNSPSC 51412302: Clobenfurol or cloridarol

This classification denotes a vasodilating agent, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier 2L2063955H. European Medicines Agency schedules Cloridarol in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB06757MIG. Cloridarol generally arises in the molecular formula C15H11CLO2.

The term CLORIDAROL is an International Non-Proprietary Name or INN (see WHO INN reference publication, Volume 27, no. 10 1973, list 13.) CLORIDAROL is scheduled in the U.S. International Trade Commission's Harmonized Tariff System (HTS) Pharmaceutical Appendix. Clobenfurol or cloridarol bears US NLM identifiers UMLS ID C0055892 and NCI Concept Code C80876. SMILES: C1=CC=C2C(=C1)C=C(O2)C(C3=CC=C(C=C3)Cl)O.

UNSPSC 51412302 Clobenfurol or cloridarol is a Commodity code that represents a narrow pharmaceutical product class, yet state and local governments procure medications under this code's parent categories for emergency medical services, health agencies, and cooperative purchasing programs serving multiple jurisdictions. The recent opportunities show state and local buyers acquiring advanced life support medications, generic multi-source pharmaceuticals, and OTC products through formal competitive procurement — goods that must meet FDA requirements, cGMP and Drug Supply Chain Security Act (DSCSA) compliance, specific expiration-date standards, and delivery timelines measured in days or weeks. Issuing bodies include municipal fire departments (Tampa Fire Rescue via the City of Tampa Purchasing Department), state health agencies (Texas Health and Human Services Commission), and regional cooperative purchasing alliances (Minnesota Multistate Cooperative Purchasing Alliance, or MMCAP, serving state and local government facilities across multiple states including Oregon).

Recent activity spans Florida, Texas, and Minnesota. The City of Tampa issued an IFB (Bid No. 26-P-00188) due April 8, 2026, for Advanced Life Support Medications including 370 units of Labetalol HCI 100mg vials, 1,810 units of Epinephrine 1:10,000 injections, 330 units of Adenosine 6mg vials, and 1,020 units of Diltiazem 25mg vials, with an estimated contract value of $40,000 and a 5 percent bid discount for Small Local Business Enterprise (SLBE) participation not to exceed $10,000. MMCAP issued an RFP due March 26, 2026, to establish multi-award contracts for generic multi-source pharmaceuticals and OTC products distributed through AmerisourceBergen, Cardinal Health, and Morris & Dickson, with pricing weighted at 75 percent and contract terms of two years with optional extensions through June 30, 2028. The Texas HHS Commission issued an RFI (HHS0017013) closed April 3, 2026, to gather vendor capabilities for a Therapeutic Pharmacy Initiative Direct-to-Manufacturer Prescriptions program, signaling future formal procurement focused on direct state-to-manufacturer contracting outside traditional pharmacy benefit manager and group purchasing organization channels.